Net Loss Per Common Share

12 Months Ended

Dec. 31, 2015

12. Net Loss Per Common Share

Since the Company had a net loss for all periods presented, the effect of all potentially dilutive securities is anti-dilutive. Accordingly, basic and diluted net loss per share is the same in those periods. The weighted-average anti-dilutive shares shown in the foregoing table were not included in the computation of diluted net loss per share. Anti-dilutive shares comprise the impact of the number of shares that would have been dilutive had the Company had net income plus the number of common stock equivalents that would be anti-dilutive had the Company had net income. Furthermore, 311,459 performance-based restricted common stock awards which vest on the one year anniversary of the U.S. Food and Drug Administration, or FDA, approval for GLATOPA in the United States (April 16, 2016) were excluded from diluted shares outstanding as the vesting condition for the amended awards, discussed further in Note 11 "Share-Based Payments," had not been met as of December 31, 2015.

The following table presents anti-dilutive shares for the years ended December 31, 2015, 2014 and 2013 (in thousands):

	2015		2014		2013
Weighted-average anti-dilutive shares related to:
Outstanding stock options		4,148		5,941		4,492
Restricted stock awards		519		847		929